A new study in an American Heart Association journal suggest doctors should be using data analysis to predict problems with implanted medial devices instead of relying on patient reporting. The researchers used off-the-shelf surveillance software to monitor large databases of implantable cardioverter-defibrillator patients.
They were able to detect problems with recalled leads a year before the manufacturer did.
Bernstein & Co. analyst Jack Scannell isn’t optimistic that biopharmaceutical companies will be able to boost their output any time soon.
From clinging to old-school methods to coping with ever expanding regulations, Scannell’s report finds a lot more problems than solutions.
This weekApple announced tool that is like Remote Desktop for iPads. Configurator will allow IT administrators at large institutions–like hospitals–to manage and configure all the iPads and iPhones in the building.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The Food and Drug Administration is considering a new way to get drugs to the market more quickly by limiting the treatments to specific groups of people. Antibiotics, weight loss drugs, and other medications could be approved without clinical trials. Dr. Janet Woodcock of the FDA’s Center for Drug Evaluation and Research discussed the idea yesterday during a break in a hearing on FDA user fees and drug approvals.
Venture investment in hospital technology is shifting from cutting-edge robots to more mundane tools to help hospitals fulfill requirements of the health care reform law and avoid financial penalties. Companies like Castlight Health and Catheter Connections are focused on saving money by helping consumers choose cheaper care and by helping hospitals reduce the cost of cathether-related blood stream infections.
